Loading stocks --

Pharma sector posts 5% YoY earnings growth in 3QCY26/1QFY27 despite Afghan export disruption

JS Research
Stock ImpactPositive

Pharma Sector Review - 3QCY26/1QFY27

Research by: JS Global | Date: November 18, 2026

Report Overview

JS Global has released a comprehensive review of the Pakistani pharmaceutical sector for 3QCY26/1QFY27, covering 9 listed companies that represent approximately 93% of the sector's market capitalization on the Pakistan Stock Exchange (PSX). During the quarter, the sample companies posted a 1% YoY revenue decline but achieved a 5% YoY growth in cumulative earnings.

Sector Financial & Business Trends

While industry data showed +12% YoY / +8% QoQ revenue growth, the listed sample reflected -1% YoY / +6.3% QoQ growth due to higher trade discounts and the suspension of exports to Afghanistan. Exports via land have been disrupted since Oct-2025 and via air since Apr-2026. However, strong gross margins—improving to an industry average of 45% (+2.4ppts QoQ / +3ppts YoY)—supported overall sector profitability through cost optimization and pricing adjustments.

Company-Wise Valuations & Financial Highlights

The pharma sector has underperformed the KSE-100 index with a 15% drop CYTD, bringing the sector trailing P/E down to 11.4x compared to its 12-month average of 18.2x. Below is a summary table of key financial metrics for sample companies:

CompanyCodeMarket Cap (Rs mn)Sales GrowthGross MarginTrailing P/E (x)
AGP*AGP43,162-4%61%12.17
GlaxoSmithKlineGLAXO106,10712%39%9.66
Abbot LabsABOT98,4584%38%10.60
Ferozsons Labs*FEROZ15,71124%45%15.08
The Searle CompanySEARL46,55218%53%11.59

Key Catalysts

  • Recovery in demand heading into the winter season with higher incidences of viral diseases.
  • Potential reopening of the Afghan border or humanitarian drug export allowances via international donor agencies.
  • Eventual drug price adjustments as demand picks up.
  • Rising demand for new products and affordable local substitutes for global brands.

Investor Takeaway

JS Global views the long-term pharma demand outlook as intact, supported by Pakistan's favorable demographics. Recent underperformance has made sector valuations attractive, presenting opportunities for medium-to-long-term investors.